Spots Global Cancer Trial Database for recurrent myelodysplastic syndrome
Every month we try and update this database with for recurrent myelodysplastic syndrome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | NCT03969446 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Decitabine Pembrolizumab Venetoclax | 18 Years - | City of Hope Medical Center | |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | NCT04493138 | Chronic Myelomo... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Myelo... Recurrent Myelo... | Azacitidine Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01892371 | FLT3 Gene Mutat... FLT3 Internal T... Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Myel... | Azacitidine Cytarabine Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | NCT04487106 | Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Myel... | Azacitidine Trametinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | NCT01822509 | Allogeneic Hema... Myeloproliferat... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Chron... Recurrent Hemat... Recurrent Hodgk... Recurrent Myelo... Recurrent Non-H... Recurrent Plasm... | Ipilimumab Laboratory Biom... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT03813147 | Acute Myeloid L... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Azacitidine Cytarabine Fludarabine Pho... Methotrexate Pevonedistat Therapeutic Hyd... | 1 Month - 21 Years | National Cancer Institute (NCI) | |
| Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | NCT02890329 | Previously Trea... Recurrent Acute... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... Secondary Acute... Secondary Myelo... | Decitabine Ipilimumab | 18 Years - | National Cancer Institute (NCI) | |
| Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | NCT04734990 | Chronic Myelomo... Chronic Myelomo... Chronic Myelomo... Myelodysplastic... Recurrent Chron... Recurrent Myelo... | Azacitidine Seclidemstat | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome | NCT05564650 | Myelodysplastic... Recurrent Myelo... Refractory Myel... | Navitoclax Venetoclax Decitabine Bone Marrow Bio... Biospecimen Col... Laboratory Biom... Quality-of-Life... | 18 Years - | Thomas Jefferson University | |
| Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant | NCT02684162 | Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Myelo... | Donor Lymphocyt... Guadecitabine Laboratory Biom... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia | NCT04239157 | Chronic Myelomo... Myelodysplastic... Recurrent Chron... Recurrent Myelo... Refractory Chro... Refractory Myel... | Canakinumab | 18 Years - | M.D. Anderson Cancer Center | |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia | NCT04375631 | Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Mixe... Refractory Myel... Refractory Acut... Refractory Acut... | Cladribine Cyclophosphamid... Cyclosporine Cytarabine Filgrastim Hematopoietic C... Mitoxantrone Mycophenolate M... Mycophenolate S... Total-Body Irra... Idarubicin Fludarabine Cytarabine Multigated Acqu... Echocardiograph... X-Ray Imaging Bone Marrow Bio... Bone Marrow Asp... | 18 Years - | Fred Hutchinson Cancer Center | |
| Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | NCT03661307 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Recurrent Myelo... Refractory Acut... | Decitabine Quizartinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | NCT04493138 | Chronic Myelomo... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Myelo... Recurrent Myelo... | Azacitidine Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | NCT03969446 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Decitabine Pembrolizumab Venetoclax | 18 Years - | City of Hope Medical Center | |
| Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant | NCT02684162 | Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Myelo... | Donor Lymphocyt... Guadecitabine Laboratory Biom... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome | NCT05564650 | Myelodysplastic... Recurrent Myelo... Refractory Myel... | Navitoclax Venetoclax Decitabine Bone Marrow Bio... Biospecimen Col... Laboratory Biom... Quality-of-Life... | 18 Years - | Thomas Jefferson University | |
| Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | NCT04128748 | Acute Myeloid L... Blasts More Tha... High Risk Myelo... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Liposome-encaps... Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia | NCT04250051 | Recurrent Acute... Recurrent Myelo... Recurrent Myelo... Refractory Acut... Refractory Myel... | Cytarabine Filgrastim Fludarabine Fludarabine Pho... Ivosidenib | 18 Years - | Northwestern University | |
| Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation | NCT03953898 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Biospecimen Col... Bone Marrow Asp... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT03772925 | Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Belinostat Pevonedistat | 18 Years - | National Cancer Institute (NCI) | |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | NCT04752163 | Hematopoietic a... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Acut... Refractory Chro... Refractory Myel... | DS-1594b Azacitidine Cyclophosphamid... Cytarabine Dexamethasone Filgrastim Leucovorin Mesna Methotrexate Posaconazole Prednisone Rituximab Venetoclax Vincristine Voriconazole | 18 Years - | M.D. Anderson Cancer Center | |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | NCT04493138 | Chronic Myelomo... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Myelo... Recurrent Myelo... | Azacitidine Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome | NCT04160052 | Chronic Myelomo... Myelodysplastic... Recurrent Myelo... Refractory Myel... Therapy-Related... | Azacitidine Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | NCT04874194 | Hematopoietic a... Recurrent Acute... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Acut... Refractory Myel... | Omacetaxine Mep... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | NCT04874194 | Hematopoietic a... Recurrent Acute... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Acut... Refractory Myel... | Omacetaxine Mep... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | NCT02890329 | Previously Trea... Recurrent Acute... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... Secondary Acute... Secondary Myelo... | Decitabine Ipilimumab | 18 Years - | National Cancer Institute (NCI) | |
| Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | NCT03969446 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Decitabine Pembrolizumab Venetoclax | 18 Years - | City of Hope Medical Center | |
| Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01892371 | FLT3 Gene Mutat... FLT3 Internal T... Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Myel... | Azacitidine Cytarabine Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | NCT04487106 | Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Myel... | Azacitidine Trametinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT03772925 | Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Belinostat Pevonedistat | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
